MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202621098705 A) filed by Dr. Sushrut Dilip Gadgil; Dr. Madhavi Dilip Gadgil; Dr. Shreyasi Sushrut Gadgil; Dr. Shruti Sagar Lele; and Jidnyasa Sushrut Gadgil on August 14, 2026, for Amrutved Number 2: An Ayurvedic Poly-Herbo-Mineral Formulation For The Management, Prevention And Adjuvant Treatment Of Cancer With Enhanced Raktaprasadana And Arsha-Dushya Targeting Activity.
Inventors include Dr. Sushrut Dilip Gadgil; Dr. Madhavi Dilip Gadgil; Dr. Shreyasi Sushrut Gadgil; Dr. Shruti Sagar Lele; and Jidnyasa Sushrut Gadgil.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: ABSTRACT AMRUTVED NUMBER 2 is a novel Ayurvedic poly-herbo-mineral formulation conceived by the late Dr. Vd. Dilip Prabhakar Gadgil, Ph.D. (Ayurveda), and clinically applied by Dr. Sushrut Dilip Gadgil, M.D. (Ayurveda), for the management, prevention and adjuvant treatment of cancer. Distinct from AMRUTVED NUMBER 1, this formulation comprises fourteen constituents: Hiraka Bhasma, Raktapachaka Churna (Patola, Sariva, Musta, Patha, Kutaki), Shukrashodhana Gana, Rasayana Churna (Gokshur, Amalaki, Guduchi), Patha and Dhamasa Churna (Cissampelos pareira and Fagonia cretica), Ananta Churna (Hemidesmus indicus), Vaikrant Bhasma, Bruhat Vata Chintamani Rasa, Vedanantaka Rasa, Suvarna Bhasma, Suvarna Makshika Bhasma, Gairik Bhasma, Shaliparni Churna and Dushivishari Agad Churna. The formulation provides enhanced Raktaprasadana, Arsha-Dushya targeting, triple anti-angiogenic activity, triple Sheeta anti-Pitta protection and a three-tier detoxification system. It is particularly indicated for colorectal cancers, soft-tissue malignancies, hematological cancers and Pitta-dominant cancer presentations requiring hepatoprotective adjuvant support.
Disclaimer: Curated by HT Syndication.
